Health
Novavax Covid vaccine highly effective, but not against S.Africa variant – Yahoo News Australia
US biotech firm Novavax said Thursday its two-shot Covid-19 vaccine showed an overall efficacy of 89.3 percent in a major Phase 3 clinical trial in Britain, …
US biotech firm Novavax said Thursday its two-shot Covid-19 vaccine showed an overall efficacy of 89.3 percent in a major Phase 3 clinical trial in Britain, and remained highly effective against a variant first identified there.
But the positive news was partly offset by other results that showed it offered significantly less protection against a highly transmissible variant of the coronavirus first identified in South Africa, which is spreading rapidly around the world.
Novavax said it began working…
-
Noosa News22 hours agoEnsure voices are heard – Proctor
-
Noosa News24 hours agoCity of Moreton Bay claims homeless people consented to having camps thrown away
-
Business19 hours agoUp 34% this year, can Challenger shares keep rising according to Macquarie?
-
General24 hours agoFederal politics live: Government says RBA rate cut decision about ‘pace, not direction’